Germany to OK knee joint, coronary reimbursement
This article was originally published in Clinica
The German joint federal committee (G-BA), an independent regulatory body that carries out health technology assessment for reimbursement purposes, last week agreed to place total knee joint endoprostheses (TKJE) and coronary intervention in the inpatient reimbursement catalogue for procedures that may be planned in advance.
You may also be interested in...
Perrigo, Pfizer want the US FDA to postpone its March 1 deadline for conducting nitrosamine risk assessments. Generics exec cites“serious compliance challenges” in conducting these assessments due to difficulty in finding the right lab equipment necessary to quantify nitrosamine daily intake limits.
Deal snapshot: For $425m up front, the pharma obtains a Phase III recombination fusion protein that shows ability to improve hospitalized patients’ clinical status and reduce risk of death.
Previous businesses FDA warned about COVID-19 claims for chlorine dioxide, a bleach solution, were marketing dietary supplements unlawfully. But Pro Breath MD's oral rinses available under the Dentist Select and OraCare brands are allowed and FDA isn’t asking the firm to discontinue distribution.